<p>AIM VACCINE (06660.HK) announced its full-year results for the year ended last December, with revenue of RMB 1.166 billion, a year-on-year decrease of 9.3%. Losses widened to RMB 675 million, compared to a loss of RMB 277 million in the same period last year; loss per share was RMB 0.55. No final dividend will be distributed</p>

159849

159316

<p>AIM VACCINE announced its full-year results for the year ended December last year, with a revenue of 1.166 billion yuan (RMB), a year-on-year decrease of 9.3%. The loss widened to 675 million yuan, compared to a loss of 277 million yuan in the same period last year; the loss per share was 0.55 yuan. No final dividend will be distributed</p>

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

AIM VACCINE

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

"Performance" AIM VACCINE's losses widened to 675 million yuan last year